ICD-10-CM Diagnosis Code (2025)
Official Description for D68.31
Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
Coding Notes & Guidelines for D68.31
- antiphospholipid antibody, finding without diagnosis (R76.0)
- antiphospholipid antibody syndrome (D68.61)
- antiphospholipid antibody with hypercoagulable state (D68.61)
- lupus anticoagulant (LAC) finding without diagnosis (R76.0)
- lupus anticoagulant (LAC) with hypercoagulable state (D68.62)
- systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
- systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.62)
- Autoimmune hemophilia
- Autoimmune inhibitors to clotting factors
- Secondary hemophilia
- Lupus anticoagulant (LAC) with hemorrhagic disorder
- Systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder
- Antithromboplastinemia
- Antithromboplastinogenemia
- Hemorrhagic disorder due to intrinsic increase in antithrombin
- Hemorrhagic disorder due to intrinsic increase in anti-VIIIa
- Hemorrhagic disorder due to intrinsic increase in anti-IXa
- Hemorrhagic disorder due to intrinsic increase in anti-XIa
Parent Code (Less Specific):
About ICD-10-CM Code D68.31 (Hemorrhagic disorder due to intrinsic circulating anticoagulants)
ICD-10-CM code D68.31 is a billable or specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2025 edition of ICD-10-CM D68.31 became effective on October 1, 2024.
This page provides detailed information about D68.31 - Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors. It includes common terminology, coding guidelines such as "Includes," "Excludes1," and "Excludes2" notes, and information on required 7th characters. Utilizing this information correctly is essential for accurate medical coding and claims submission for conditions like Hemorrhagic disorder due to intrinsic circulating anticoagulants related to antibodies, or inhibitors.